<DOC>
	<DOCNO>NCT01494233</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy LX1033 range dose level subject diarrhea-predominant Irritable Bowel Syndrome ( IBS ) .</brief_summary>
	<brief_title>A Multi-Center Trial Determine Safety Efficacy LX1033 Subjects With Diarrhea-Predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Male female subject , age 18 70 year , diarrheapredominant IBS ( IBSD ) symptom onset least 6 month prior diagnosis Two day per week least one stool consistency Type 6 7 ( Bristol Stool Form Scale ) Weekly average worst abdominal pain past 24 hour score great equal 3.0 use 010 point scale Ability provide write , informed consent Inability discontinue current drug therapy IBS , exception bulking agent . Subjects allow 2 dos loperamide per week rescue medication . Subjects score severe abdominal pain ( rat 7 high ) 5 day per week Concomitant use opioid analgesic drug drug affect bowel motility Any abnormality condition deem investigator clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>